Methylselenocysteine (Se-Methylselenocysteine)
Identity, Chemistry, and Natural Sources
Methylselenocysteine (Me-Sec), also known as Se-methylselenocysteine (SeMSC), is an analog of S-methylcysteine in which the sulfur atom is replaced with a selenium atom. It is a selenoamino acid — a naturally occurring, non-proteinogenic amino acid containing selenium — and is classified as an organic selenium compound. Its CAS number is 1464-43-5, its molecular formula is C₄H₉NO₂Se, and its molecular weight is 184.08 g/mol. In its purified supplemental form, it appears as a white powder or granules with a garlic-like odor. The compound is most commonly referred to in the scientific literature by several synonyms including SeMSC, SeMC, MSeC, Me-Sec, Se-MSC, and L-Se-methylselenocysteine, with the L-enantiomer being the biologically relevant and commercially distributed form.
Se-methylselenocysteine (MSC) is a naturally occurring selenium compound that has very favorable pharmacokinetic properties with high peroral bioavailability in humans. Organic selenium species, including selenoamino acids such as selenomethionine (SeMet), selenocystine (SeCys₂), and Se-methylselenocysteine (MSC), generally provide greater bioactivities with less toxicity compared to inorganic forms including selenite (Se IV) and selenate (Se VI).
Natural Botanical Sources
Methylselenocysteine is found in many vegetables: as much as 80% of the total selenium found in Allium species (onion, leek, garlic, ramps), Brassica species (broccoli, radish, Brussels sprouts, cabbage), and milk vetch (Astragalus species, Fabaceae) is present as Se-methylselenocysteine. It is also present in selenized yeast (Saccharomyces cerevisiae grown in a high-selenium culture).
Broccoli (Brassica oleracea var. italica) is known for its ability to accumulate high levels of selenium, with the majority of the selenoamino acids in the form of Se-methylselenocysteine. Selenium is present in plant foods in different chemical forms, including the organic selenium-containing amino acids Se-methylselenocysteine (MeSeCys) and its glutamyl precursor, γ-glutamyl-Se-methylselenocysteine (γ-GluMeSeCys), in addition to inorganic forms selenite and selenate.
A notable precursor relationship governs the compound's abundance in some plants. In selenium-accumulating plants, the predominant form of selenium is γ-glutamyl methylselenocysteine. The organic compound γ-glutamyl methylselenocysteine, found in brassica and allium vegetables, is first converted to Se-methylselenocysteine upon digestion or processing. In plants, SeMSC is produced by a dedicated selenocysteine methyltransferase.
Astragalus bisulcatus is a primary selenium hyperaccumulator species that grows in soils with high selenium concentrations, capable of accumulating up to 0.6% of its shoot dry weight as methylselenocysteine. This plant exhibits a significant conversion of inorganic selenium in older leaves to organic forms, particularly in its young leaves and roots. Selenium hyperaccumulators avoid selenium toxicity by methylating selenocysteine to methylselenocysteine via a unique enzyme, selenocysteine methyltransferase, effectively circumventing the misincorporation of selenocysteine into protein.
Common Forms and Preparations
SeMSC is commercially available in several forms. As a dietary supplement, it is marketed as a purified crystalline free amino acid, typically as the L-form hydrochloride salt or as the free base, incorporated into processed food, capsules, tablets, powders, gels, or liquids. It is also obtained indirectly through the consumption of selenium-enriched plants. It is also present in selenized yeast (Saccharomyces cerevisiae grown in a high-selenium culture). Adding inorganic selenium to the soil increases the expression of the selenocysteine methyltransferase gene in plants, a principle exploited to biofortify agricultural crops with SeMSC.
Discovery and Scientific History
Although seleniferous plants had been recognized as toxic to grazing livestock in the American Great Plains since at least the 1930s, the precise organic selenium compounds responsible were unknown for decades. Horn and Jones (1940) were the first to isolate an organic selenium compound from plant material; they isolated a mixture from water extracts of Astragalus pectinatus that they considered to be the isomorphic compounds cystathionine and Se-cystathionine. Later, Trelease et al. (1960) reported the isolation of Se-methylselenocysteine from Astragalus bisulcatus. This 1960 publication in Science — using ion-exchange and filter-paper columns to separate amino acids — identified two amino acids: S-methylcysteine and Se-methylselenocysteine, formally establishing SeMSC as a distinct molecular entity.
Se-methylselenocysteine (SeMC) is a naturally occurring organoselenium compound first identified in Astragalus bisulcatus (Trelease et al., 1960). Biochemical studies on accumulator species of Astragalus have shown that Se-methylselenocysteine is formed by the methylation of selenocysteine.
Scientific interest in SeMSC as a potential health-promoting agent accelerated substantially following the publication of the Nutritional Prevention of Cancer (NPC) Trial in 1996, which demonstrated cancer incidence reduction using selenium-enriched yeast. In the Nutritional Prevention of Cancer Trial, selenized yeast resulted in "a reduction in the incidence of prostate cancer and in total cancer incidence"; subsequent anticancer studies using selenomethionine did not show any benefit against cancer; but, selenized yeast contains both selenomethionine and methylselenocysteine. This discrepancy prompted researchers to investigate whether SeMSC — present in selenium-enriched yeast alongside selenomethionine — might account for the observed benefits that selenomethionine alone could not replicate.
Traditional and Historical Use
Se-methylselenocysteine as a chemically isolated, named compound has no documented history of deliberate traditional use in any established herbal or folk medicine system. It was not known as a distinct chemical entity before 1960. The relevant traditional context is therefore that of the selenium-accumulating plants in which it is abundant, particularly garlic (Allium sativum) and closely related species, which have long histories of culinary and medicinal use in many cultures — including ancient Egyptian, Greek, Roman, Indian (Ayurveda), and Chinese traditions. However, these traditions directed their use toward the whole plant or its sulfur-rich volatile compounds, with no documented awareness of selenium speciation or SeMSC content.
Populations living in regions of naturally selenium-rich soils and consuming selenium-accumulating plants would have received dietary SeMSC without any deliberate intent. The recognition of this compound as a bioactive entity is entirely a product of modern analytical chemistry and nutritional biochemistry, beginning in the second half of the twentieth century and intensifying from the 1990s onward with the emergence of selenium chemoprevention research.
Biosynthesis in Plants and Chemical Ecology
A cDNA encoding selenocysteine Se-methyltransferase — the key enzyme responsible for SeMSC formation — was cloned from broccoli using a homocysteine S-methyltransferase gene probe from Arabidopsis thaliana. Selenocysteine methyltransferase is the enzyme responsible for the biosynthesis of Se-methylselenocysteine from selenocysteine and S-methyl-methionine.
Studies of the distribution of selenomethylselenocysteine and glutamylselenomethylselenocysteine in Astragalus bisulcatus indicate that the free amino acid is the principal selenoamino acid in vegetative parts, whereas the seeds are richer in the glutamyl peptide. During germination the peptide is probably hydrolyzed to free Se-methylselenocysteine, which is present in one-week-old seedlings in larger quantities than the peptide, and the quantity of the peptide further declines as the seedlings grow so that in one-month-old plants the amino acid bound selenium is present primarily as free Se-methylselenocysteine.
The finding that accumulator and non-accumulator plants differ in their capacity to synthesize this metabolite suggests it functions as a nontoxic dead-end selenium metabolite in hyperaccumulator species, allowing them to tolerate otherwise toxic soil selenium levels.
Key Constituents and Active Compounds
As a single molecular entity, SeMSC is itself the subject of study rather than a plant extract containing multiple active components. However, its biological activity is intimately connected to the metabolites it generates upon enzymatic processing in mammalian and plant tissues.
Metabolic Activation: The Methylselenol Pathway
Specifically, SeMSC "is converted via the action of β-lyase, to methylselenol and then to hydrogen selenide," which is also the key metabolite derived from all other common forms of selenium. This metabolic conversion is central to understanding the compound's biological effects. Unlike L-selenomethionine and selenized yeast currently used in clinical prevention trials, MSeC binds poorly to general body proteins and is activated in one step by β-lyase to the presumed active metabolite methylselenol.
Methylselenol from selenium metabolism is postulated to be — and most experimental evidence now indicates that it is — the selenium metabolite responsible for the dietary chemoprevention of cancers. Methylselenol and other redox-cycling selenium compounds are almost certainly accountable for inducing cell-cycle arrest and apoptosis in cancer cells in vitro and in vivo.
SeMSC is considered a pro-drug because the compound itself is not toxic unless it is metabolized by the enzymes Kynurenine aminotransferase 1 (KYAT1), Kynurenine aminotransferase 3 (KYAT3), and cystathionine γ-lyase (CTH). In mammals, MSC is metabolized primarily by kynurenine aminotransferase 1 (KYAT1), a multifunctional, pyridoxal 5′-phosphate (PLP)-dependent enzyme.
A key mechanistic distinction between SeMSC and selenomethionine is the directness of metabolic activation. Selenium compounds that are able to generate a steady stream of methylated metabolites, particularly the monomethylated species, are likely to have good chemopreventive potential; anticarcinogenic activity is lower for selenoamino acids, such as selenocysteine following conversion from selenocystine, which have an escape mechanism via random, nonstoichiometric incorporation into proteins. Selenomethionine can be incorporated non-specifically into body proteins in place of methionine, creating a large tissue reservoir that does not necessarily generate active methylated metabolites. SeMSC, lacking this incorporation pathway, proceeds more directly to active species.
γ-Glutamyl Precursor
γ-Glutamyl Se-methylselenocysteine is reported to be the major form of selenium in selenium-enriched garlic, while L-selenomethionine is the major form of selenium in selenium-enriched yeast. Laboratory studies indicate that γ-Glutamyl-Se-methyl-L-selenocysteine is an effective chemopreventive agent, serving as a carrier for Se-Methyl-L-selenocysteine.
Established Mechanisms of Action
Induction of Apoptosis
Several mechanisms have been proposed for the chemopreventive activity of selenium, including induction of apoptosis, inhibition of angiogenesis, and arrest of cell cycle. SeMSC is a "chemopreventive agent that blocks cell cycle progression and proliferation of premalignant mammary lesions and induces apoptosis of cancer cell lines in culture." Apoptosis has been proposed as the most plausible mechanism for the chemopreventive activities of selenocompounds. Se-methylselenocysteine was more efficient at inducing apoptosis than selenite, but was less toxic.
Methylselenol is known for its action to selectively kill transformed cells through mechanisms that include increased formation of reactive oxygen species, induction of DNA damage, triggering of apoptosis, and inhibition of angiogenesis. SeMSC rapidly and specifically downregulates expression of Bcl-2 at the transcriptional level; the forced expression of Bcl-2 attenuated SeMSC-plus-TRAIL-mediated apoptosis, suggesting that lessened Bcl-2 expression caused by SeMSC treatment is critical to increased sensitivity to TRAIL in renal cancer cells. In addition, the synergistic effects of SeMSC and TRAIL result from the activation of caspase-dependent pathways.
Inhibition of Angiogenesis
Angiogenesis is affected by methylselenol precursors because of its inhibition of VEGF from several cancer cell lines. Antiangiogenic effects of MSC result in tumor growth inhibition, vascular maturation in vivo, and enhanced anticancer drug delivery that are associated with therapeutic synergy in vivo. This tumor vascular normalization effect — where chaotic, leaky tumor vessels are made more structurally regular — has been proposed as a mechanism by which SeMSC might enhance the delivery of co-administered chemotherapy drugs to tumor tissue.
Cell Cycle Arrest
MSC is a promising chemopreventive agent against in vivo and in vitro models of carcinogen-induced mouse and rat mammary tumorigenesis; it has been demonstrated that MSC induces apoptosis after a cell growth arrest in S phase in a mouse mammary epithelial tumor cell model (TM6 cells) in vitro.
PI3K/Akt Pathway Inhibition
Synergy between SeMSC and docetaxel in prostate cancer cells was associated with induction of apoptotic cell death, which was associated with caspase-3 activation and downregulation of the antiapoptotic protein survivin. Studies of PI3K pathway involvement in mammary tumor cells found that SeMSC inhibited phosphatidylinositol 3-kinase activity, further contributing to its pro-apoptotic and anti-proliferative effects.
Epigenetic and Circadian Pathway Modulation
Metabolites of SeMSC and SeMet inhibit HDAC activity, and methylselenol is able to inhibit PKC activity by redox modifications of cysteines. Methylselenocysteine resets the rhythmic expression of circadian and growth-regulatory genes disrupted by nitrosomethylurea in vivo. The expression of Per2 and DBP mRNAs was significantly decreased in mammary tumors arising in rats on the selenium-enriched diet, suggesting that selenium-induced elevation in the expression of circadian genes was incompatible with mammary carcinogenesis. These observations suggest that Per2 is an important target of methylselenocysteine during chemoprevention, providing for the first time a link between chemoprevention and circadian rhythm.
NF-κB Pathway
Most known chemopreventive agents, including certain selenium compounds, suppress the activation of nuclear factor kappa-B (NF-κB). Selenium methylselenocysteine (Se-MeSeCys) is a common selenocompound in the diet with a tested chemopreventive effect; one study showed that treatment of HepG2 cells with concentrations of Se-MeSeCys in the nanomolar to micromolar range confers significant protection against an oxidative insult.
Scientific Evidence by Health Area
Cancer Chemoprevention
Preclinical Evidence (Animal Models)
The most extensive body of evidence for SeMSC concerns cancer chemoprevention, and the large majority of this evidence comes from cell culture and animal studies. The chemopreventive activities of Se-methylselenocysteine were evaluated in the rat dimethylbenz(a)anthracene (DMBA)-induced mammary tumor model. Results of the carcinogenesis experiments showed that the relative efficacy with the four selenium compounds tested was Se-methylselenocysteine greater than selenite greater than selenocystine greater than dimethyl selenoxide.
The distinction between SeMSC and methylseleninic acid in terms of chemopreventive efficacy disappeared in vivo, where their cancer chemopreventive efficacies were found to be very similar to each other in both methylnitrosourea and DMBA rat mammary tumor models. The β-lyase enzyme is present in many tissues; thus, animals have an ample capacity to metabolize Se-methylselenocysteine systemically. Therefore, Se-methylselenocysteine would be expected to behave like methylseleninic acid if β-lyase is no longer a limiting factor.
While different forms of selenium vary in their anticarcinogenic efficacy, Se-methylselenocysteine (SeMSC) has been demonstrated to be one of the most effective chemopreventive compounds in experimental models. Se-methylselenocysteine has been shown to have chemopreventive properties in various cell culture models and animal models, and has also been shown to have anti-carcinogenic properties by inducing cell cycle arrest and apoptotic cell death.
Mammary Cancer
Studies in rodent models using chemically induced mammary tumors (DMBA and NMU models) have consistently shown that dietary SeMSC supplementation reduces tumor incidence, burden, and multiplicity. In one study in rat mammary carcinogenesis, expression of the circadian gene Per2 was significantly decreased in mammary tumors arising in rats on the selenium-enriched diet but not in tumors of rats on the control diet, suggesting that selenium-induced elevation in the expression of circadian genes was incompatible with mammary carcinogenesis, and providing a link between chemoprevention and circadian rhythm.
Prostate Cancer
Selenium is being evaluated as a chemopreventive agent in patients with prostate, colon, and lung cancer with promising results. Methylselenocysteine (MSeC) is a selenium-containing compound; unlike L-selenomethionine and selenized yeast currently used in clinical prevention trials, MSeC binds poorly to general body proteins and is activated in one step by β-lyase to the presumed active metabolite methylselenol. Many epidemiologic observations and clinical trials support the hypothesis that selenium protects against the risk of prostate cancer.
A study evaluated the combination treatment of methylselenocysteine (MSeC) and docetaxel and delineated the underlying mechanism associated with observed in vitro synergy between MSeC and docetaxel in prostate cancer cells. Pretreatment of C2G prostate cancer cells with MSeC followed by docetaxel was found to be critical for achieving synergy in this in vitro model.
Head and Neck Cancer — Antiangiogenic/Combination Synergy
The therapeutic synergy between naturally occurring selenoamino acid methylselenocysteine (MSC) and anticancer drugs could not be shown in vitro; studies were carried out to investigate the potential role of MSC-induced tumor vascular maturation and increased drug delivery in the observed therapeutic synergy in vivo. Mice bearing subcutaneous FaDu human head and neck squamous cell carcinoma xenografts were treated with MSC (0.2 mg/d × 14 days orally). The antiangiogenic effects observed in this preclinical model support the concept that SeMSC may "normalize" tumor vasculature and thereby enhance delivery of co-administered cytotoxic drugs.
Clinical (Human) Evidence for Cancer Chemoprevention
There are no completed, published randomized controlled clinical trials using isolated SeMSC alone as an intervention agent in cancer prevention or treatment in humans. The human evidence is indirect. In the Nutritional Prevention of Cancer Trial, selenized yeast resulted in "a reduction in the incidence of prostate cancer and in total cancer incidence"; subsequent anticancer studies using selenomethionine did not show any benefit against cancer; but, selenized yeast contains both selenomethionine and methylselenocysteine. This observation has led researchers to hypothesize that SeMSC — present in selenized yeast but absent from pure selenomethionine preparations — may have contributed to the positive NPC Trial results. However, this remains a hypothesis; the NPC Trial was not designed to isolate SeMSC's contribution, and no direct causal inference can be drawn from that data alone.
Nearly a dozen human clinical trials with selenomethionine and selenized yeast for the prevention of non-cutaneous solid organ cancers in North America and European countries conclusively refuted their utility. Two lessons have been articulated from these trials: (1) the antioxidant hypothesis was tested in inappropriate selenium-adequate populations, and (2) the selection of these selenium forms was not supported by cell culture and animal efficacy data. Nevertheless, preclinical studies of proximal methylselenol precursors have shown many desirable attributes, involving crucial molecules and pathways in cancer epithelial cells, vascular endothelial, immune and inflammatory cells in the tumor microenvironment, for potential use as chemopreventive and therapy agents.
The European Food Safety Authority (EFSA) concluded that "given the absence of human studies on Se-methylselenocysteine, the relatively sparse database on the bioavailability of selenium from this source and the limited data on the safety of this source compared with other selenium compounds, the Upper Limit for selenium defined by the Scientific Committee on Food cannot be used for judging its safety."
Evidence strength for cancer chemoprevention: Preclinical evidence (animal models and cell culture) is substantial and mechanistically well-characterized. Human clinical evidence specific to SeMSC is absent. The totality of evidence is promising but remains preclinical in character.
Antioxidant Function and Selenoprotein Support
Selenium has been shown to be an essential micronutrient that modulates cardiovascular, immune, metabolic, and thyroid functions via its incorporation into selenoproteins as the amino acid selenocysteine. Selenoproteins have important roles in redox biology, especially selenoproteins with known roles in antioxidant and redox function, such as glutathione peroxidases (GPxs), thioredoxin reductases (Txnrd), and methionine-sulfoxide reductase (MsrB1).
In a bioavailability study using Se-methylselenocysteine, dimethyl selenoxide, and trimethylselenonium as the starting compounds for delivering selenium, researchers measured the ability of these compounds to restore glutathione peroxidase activity in selenium-depleted animals. All three compounds were able to fully replete this enzyme, although with a wide range of efficiency (Se-methylselenocysteine greater than dimethyl selenoxide greater than trimethylselenonium).
MeSeCys was incorporated into selenoprotein P slightly more than or at a comparable level to that of selenomethionine, but less than that of selenite in rat studies using stable isotope tracers.
Evidence strength: Mechanistic evidence from animal models supports SeMSC as a bioavailable selenium source capable of supporting antioxidant selenoprotein activity. Direct human studies specifically with SeMSC on antioxidant endpoints are lacking.
Cardiovascular System
In foods, selenium can be found in organic forms including methylselenocysteine and γ-glutamyl methylselenocysteine. The cardiovascular relevance of selenium generally — and of SeMSC as a dietary selenium source specifically — operates through the broader role of selenoproteins in protecting the cardiovascular system from oxidative stress. Selenium is an essential element involved in various biological processes in nearly all tissues of animals and humans, including protection against oxidative stress in the cardiovascular system. No clinical studies have specifically isolated the cardiovascular effects of SeMSC supplementation. Evidence in this domain is extrapolated from general selenium biochemistry.
Evidence strength: Indirect and extrapolatory; no SeMSC-specific cardiovascular human clinical trials identified in the literature.
Neuroprotection
Selenium demonstrates protective properties in neoplastic and cardiovascular diseases, and its insufficiency in humans has been associated with an increased risk of Alzheimer's and Parkinson's disease. In cell-based research, SeMSC has been investigated in neuroblastoma cell lines. Apoptosis of tumor cells is beneficial because it can terminate cell growth and decrease metastasis of tumors; however, excessive and inappropriate cell death can cause neurological diseases such as Alzheimer's disease and Parkinson's disease. In SH-SY5Y and N2a neuroblastoma cells, SeMSC at 1 μM demonstrated effects on apoptosis-related proteins, modulating Bcl-2/Bax ratios, suggesting a potential neuroprotective role — though this evidence is entirely in vitro.
Evidence strength: Preliminary in vitro data only. No human clinical evidence for neuroprotection specific to SeMSC.
Immune Function
Selenium modulates immune function via its incorporation into selenoproteins. SeMSC, as a bioavailable organic selenium source, would be expected to contribute to selenoprotein synthesis relevant to immune function, but no clinical trials have specifically tested SeMSC supplementation on immune parameters in humans. This domain is supported only by mechanistic reasoning and general selenium biochemistry.
Bioavailability and Pharmacokinetics
Se-methylselenocysteine is a naturally occurring selenium compound that has very favorable pharmacokinetic properties with high peroral bioavailability in humans. In an in vitro membrane permeability study using Caco-2 cells, selenomethionine and Se-methylselenocysteine were more efficiently transported than the other bioselenocompounds tested.
MSC has high bioavailability in humans and displays favorable pharmacokinetic properties with a short half-life and low risk for chronic selenosis. This short half-life distinguishes it from selenomethionine. Selenomethionine is nonspecifically incorporated into proteins as the amino acid methionine, providing a reversible selenium storage in organs and tissues — an effect that prolongs the biological half-life of selenium derived from selenomethionine but also means it cannot directly generate monomethylated metabolites unless first processed through the transsulfuration pathway. SeMSC lacks this non-specific protein incorporation, and its more direct metabolic route to methylselenol is considered a pharmacokinetic advantage for those applications requiring generation of active methylated selenium species.
A study in which cancer patients were treated orally with sodium selenite (SS), L-selenomethionine (SeMet), or Se-methylselenocysteine (MSC) at 400 µg/day for 28 days sought to investigate how these chemical forms of selenium affect plasma selenium distribution, aiming to identify the most effective selenium compound for optimal selenoprotein expression. Measurements of total selenium in plasma samples collected before and after 4 weeks of treatment showed that median total selenium levels increased significantly, particularly when SeMet was administered. This finding indicates that selenomethionine raises total plasma selenium more than SeMSC at equivalent doses, consistent with its non-specific protein incorporation, while SeMSC provides a more direct route to active metabolites without large tissue accumulation.
Dosage Forms and Reported Dosages
Dosages of SeMSC in research settings vary considerably by experimental context. The following dosages are reported directly in cited sources:
- In a mouse xenograft model of head and neck squamous cell carcinoma, MSC was administered at 0.2 mg/day × 14 days orally.
- In a subchronic toxicity study to characterize MSC toxicity, CD rats received daily gavage doses of 0, 0.5, 1.0, or 2.0 mg/kg/day (0, 3, 6, or 12 mg/m²/day), and beagle dogs received daily gavage doses of 0, 0.15, 0.3, or 0.6 mg/kg/day (0, 3, 6, or 12 mg/m²/day) for 28 days.
- The repeated dose toxicity study indicated little systemic toxicity of SeMC at supernutritional levels of 0.5, 0.7, and 0.9 mg/kg BW/day after 90-day oral exposure.
- In a human study of cancer patients, MSC was administered orally at 400 µg/day for 28 days alongside comparison selenium forms.
- For therapeutic (as opposed to chemopreventive) use in preclinical animal models, approximately 72-fold higher daily doses than the chemopreventive dose of 200 µg/day of selenomethionine were used with MSC to obtain a threshold plasma selenium concentration of 15 μM.
- In cell culture, SeMSC at 1 μM was used to treat neuroblastoma cells.
There is no established human Recommended Dietary Allowance (RDA) or tolerable upper intake level (UL) specific to SeMSC as a supplement, distinct from the general selenium UL. The NIH Office of Dietary Supplements' dietary reference values for selenium apply to total selenium intake from all sources, not to SeMSC specifically.
Safety Considerations
Acute Toxicity
SeMC, with the Median Lethal Dose (LD₅₀) of 12.6 and 9.26 mg/kg body weight in female and male mice respectively, shows high potential for health hazard under acute oral exposure. These values indicate that acute high-dose exposure is hazardous, consistent with the general toxicology of selenium compounds. However, the doses at which acute toxicity is observed are far above any proposed supplemental or dietary intake levels.
Subchronic Toxicity
The study aimed to evaluate the safety of SeMC and provide the Acceptable Daily Intake (ADI) for its use in human diet. A battery of tests including the Ames test, micronucleus assay, and mouse sperm malformation assay suggested that SeMC was not genotoxic. The repeated dose study indicated little systemic toxicity of SeMC at supernutritional levels (0.5, 0.7, 0.9 mg/kg BW/day) after 90-day oral exposure.
Genotoxicity
A battery of tests including the Ames test, micronucleus assay, and mouse sperm malformation assay suggested that SeMC was not genotoxic. This is a meaningful safety-relevant finding, particularly for a compound proposed for cancer chemoprevention.
Speciation-Dependent Toxicity
The toxicity of selenium is dependent on its chemical speciation. Generally, inorganic selenium species such as selenite are more toxic than organic selenium species such as selenomethionine, and naturally occurring selenium compounds are less toxic than artificial selenium compounds. SeMSC is positioned favorably within the organic selenium compounds in terms of acute toxicological profile, though it is not free of toxicity at excessive doses. Excessive incorporation of selenoamino acids into proteins can lead to structural malformation or loss of enzymatic activity in some sulfur-containing proteins due to the replacement of sulfur in sulfhydryl groups or thiols with selenium. SeMSC, by contrast, is not incorporated into proteins in this non-specific manner, which is considered a safety advantage.
EFSA Regulatory Position
EFSA concluded that "given the absence of human studies on Se-methylselenocysteine, the relatively sparse database on the bioavailability of selenium from this source and the limited data on the safety of this source compared with other selenium compounds, the Upper Limit for selenium defined by the Scientific Committee on Food cannot be used for judging its safety." This regulatory assessment underscores the incompleteness of the human safety data set and the inability to straightforwardly apply existing selenium ULs — established largely on the basis of inorganic and selenomethionine data — to SeMSC.
Chronic Selenosis Risk
Chronic selenosis is a group of diseases associated with a wide range of symptoms from hair loss, bone and joint problems, and cellular damage from reactive oxygen species which increase the high risk of cancers. MSC displays favorable pharmacokinetic properties with a short half-life and low risk for chronic selenosis compared to selenium compounds that accumulate in tissues, such as selenomethionine. The short half-life and absence of non-specific protein incorporation are considered factors that reduce but do not eliminate the risk of accumulative selenium toxicity with chronic SeMSC use.
Interactions
No specific pharmacokinetic drug-drug interaction studies with SeMSC have been identified in the peer-reviewed literature. The most pharmacologically relevant interaction context identified in preclinical research is the combination with chemotherapy agents. Antiangiogenic effects of MSC result in tumor growth inhibition, vascular maturation in vivo, and enhanced anticancer drug delivery that are associated with therapeutic synergy in vivo, suggesting that SeMSC at therapeutic doses may alter the pharmacodynamics of co-administered cytotoxic drugs in oncological settings. Synergy between SeMSC and docetaxel was associated with induction of apoptotic cell death, caspase-3 activation, and downregulation of the antiapoptotic protein survivin in prostate cancer cell lines. These interactions are currently characterized only in preclinical models.
As a selenium compound, SeMSC also has the general potential to interact with other antioxidants (e.g., vitamin C, vitamin E) and with compounds that affect glutathione metabolism, though the clinical significance of these interactions for SeMSC specifically has not been established in human studies.
Summary of Evidence Strength by Area
- Cancer chemoprevention (mammary, prostate, colon): Mechanistically well-supported by cell culture and animal model data; no completed randomized human clinical trials using isolated SeMSC. Evidence is preclinical.
- Antiangiogenic/combination chemotherapy synergy: Demonstrated in preclinical animal xenograft models; no human data.
- Antioxidant/selenoprotein support: Supported by animal bioavailability studies and mechanistic data; high peroral bioavailability confirmed in available human pharmacokinetic data, but clinical endpoint trials lacking.
- Neuroprotection: Preliminary in vitro data only.
- Cardiovascular and immune function: Inferred from general selenium biology; no SeMSC-specific human studies.
- Safety: Animal toxicology studies suggest low genotoxicity and manageable subchronic toxicity at supernutritional doses; human safety data are absent, and EFSA has explicitly noted this gap.
References
Go back